Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RE: RPRX INSIDER BUYING QUANTUMDOT
I believe that the whole world was aware that they were going to be announcing news by the end of Dec, and I am fairly certain that once the data was crunched they announced it immediately. IOW he was unaware of the outcomes when he bought.
yes I realized after the time to edit had expired that I should have specified "at the very latest, yesterday"
I did wonder why any buying still existed even yesterday
LOOK OUT BELOW!
Given that even if this cockamamee scheme to buy gas wells is not a complete fabrication, the trade settlement date for any buying after yesterday would be after Dec 25* so there's no more reason to buy even IF ou believe that you'll somehow benefit from THIS record date.....
*As compensation to its shareholders for the asset separation of PDEI, all GFCI shareholders of record as of close of business 5 p.m. (PST) on December 25, 2006
what business? Isn't there some federal holiday on the 25th?
didn't the stock tank after the last (meaningless) record date?
RE; Thomas / RPRX
The market for endometriosis alone is just obscenely large. Add in uterine fibroids and you've got 2.5B sales easily, especially if they can keep taking the drugs continuously for years. There are so many women out there suffering that don't even show up on the radar screen because there's just nothing for them to do. They take their ibuprofen handfuls at a time, because they know there's only one option- hysterectomy.
Proellex alone, in the growth phase of sales puts RPRX into the $3-4B categroy but the time frame is in question. AS you probably know these hormone modulators are tricky and the FDA might give them a few hoops (2-3 PIII trials) before they can actually produce and sell.
Still with the encouraging news we saw this week, $30 would be low normal for this type enterprise in this stage of development.
People seriously underestimate what a problem this is for millions and millions of women.
Trinity,
Have I ever even remotely addressed you or your posts in any way? I really cannot remember, but if I have please indicate to me where you would get off mocking me that way.
There are some people that frequent this board that are sneaky as snakes, lying, decieving, fabricating "information" for their own personal gain, manipulating numbers to make this appear as a legitimate "investment"; from some of these people, I would expect such rude behavior. From someone I've never even crossed paths with, I'm slightly perterbed. or is it preterbed? Anyways, I'm it. Knock it off please.
tenjewberrymud
I suggest you go talk to one of your finance professors at St. Bonnie.
Cyo, strangely enough I was talking to one of my prof's (my advisor) earlier this week and I was telling him about this conversation - we're talking about doing a paper on the acceleration of the degradation of the time premium during the last 4 weeks until strike as calculated by the Black Scholes option pricing formula linear vs exponential?; otherwise I wouldn't dream of bothering him with such a ridiculous discussion as this.....
his words were, "that's ridiculous (I kid you not) if this person doesn't understand such a simple concept as that he or she has no business being anywhere near the stock market much less shorting stocks"
but, like eveyone else here, I'm done with it now, you're not even in the ballpark with this one, heck you're not even playing the same sport.....and like trying to teach a fish to ride a bicycle, trying to help you understand this most basic of concepts is probably futile. No, it definitely is.
3 people each open an investment account for $100,000. A few days later all three cash out the investment account which had grown to $110,000. The gain for all three is $10,000 or 10%. That's the numerical value. No matter how you look at it the gain is 10% on all three accounts....end of story This is where your stuck.
Cyo, I'm not stuck, you are.
tampa Im slightly offended
I'm a smart person, very intelligent, and usually right about my stocks and investments
why does it hurt to agree with me? after all, agreeing with me is most of the time being correct :)
TOBIN SMITH
He has several subscriptions. This was one of his "microcap investor" picks along the lines of March-Feb this year, at less than $1.00
Some are combinations, IOW if you sign up for his "inner circle" for $5000 you get a few of the microcap picks or even inclusion on the service itself, or you can pay $1500 for the microcap.
I don't pay for either but have done the changewave before and made money.
cyo-
no offense but ther eis virtually not one person on earth who would agree with you that a ROI of a stock going from 100, to 0 results in anything but a 100% ROI when shorted during that time.
Under your argument, the return would be infinity
RPRX
I hate to sound like a pumper, but this is probably EASILY worth $20 here, and upwards from there to $40 once the overhang from the financing gets gone.
At $7.50 or whatever it opens at, it's a no brainer double in a month or less.
RE:DEAR SANTA,MAYBE IT'S RPRX
RPRX MORE GREAT NEWS
Repros' Proellex Shows Statistically Significant Improvement in Bleeding and Pain in Phase 2 Trial
12/21/2006 6:00:08 AM
THE WOODLANDS, Texas, Dec 21, 2006 (BUSINESS WIRE) -- Repros Therapeutics Inc. (NasdaqGM:RPRX) (PCX:RPRX) announced interim results of a U.S. Phase 2 study of Proellex(TM), an oral drug being developed to relieve symptoms of uterine fibroids. The Company has closed enrollment in the trial at 128 patients. Interim results from this study suggest that treatment with Proellex results in a statistically highly significant improvement in multiple symptoms associated with uterine fibroids.
Study Details and Results
This 12 week, double-blind study compares two doses of Proellex, 12.5mg and 25mg, to placebo. The study's primary endpoint is reduction in excessive menstrual bleeding, a common symptom of uterine fibroids. This endpoint was assessed using a validated visual analog scale known as the Pictorial Blood Loss Assessment Chart (PBAC). Further, pain associated with fibroids was assessed using a well validated tool, the McGill pain score, and various other symptoms associated with fibroids were assessed using the validated Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire. To date, 63 patients have completed the 12 week study and have had analyses completed for their study parameters.
Women on Proellex experienced a dramatic reduction in PBAC from mean scores of over 100 to scores less than 10. The mean scores after three months of dosing for the 25mg and 12.5mg dose of Proellex were 6.9 and 12.6 respectively. Women on placebo, on the other hand, exhibited a score of 91 after 3 months of treatment. The 12.5mg and 25mg doses were statistically superior to placebo with p-values of 0.00003 and 0.000005, respectively.(WOW!!!)
Women treated with 12.5mg and 25mg of Proellex for three months also experienced a reduction in UFS-QOL measures from an average baseline of 16 to scores of 5.3 and 5.15, respectively. UFS-QOL scores for women in the placebo arm decreased from an average baseline of 16 to 12.6 after three months. The 12.5mg and 25mg doses were statistically superior to placebo with p-values of 0.0046 and 0.0029, respectively.
Women on Proellex experienced on average a reduction of 33.6 and 33.2 in McGill pain scores for the 25mg and 12.5mg dose respectively. Women on placebo experienced an average reduction of 8.4 over the same three month period. The 12.5mg and 25mg doses were statistically superior to placebo with p-values of 0.045 and 0.006, respectively.
After three months on treatment, no statistically significant changes in endometrial thickness were detected among 100 women who underwent ultrasound measurements of endometrial thickness at various time points. This study uses an endometrial thickness cut-off of 14mm after three months of dosing to determine whether or not a woman is allowed to proceed into an ongoing open label study. At this time 16 patients have had endometrial thicknesses greater than 14mm. Seven of the patients were on placebo, six were on the 12.5mg dose and 3 were on the 25mg dose. Importantly, to date, of the women who have had endometrial biopsies and have been on active drug there has been no evidence of endometrial hyperplasia with atypia, a potential precursor for endometrial cancer.BEST NEWS POSSIBLE!!!
"We are very pleased with these results," commented Joseph Podolski, President and CEO of Repros. "This is the second indication in which Proellex has demonstrated profound effects in relieving symptoms in significant female indications for which there have been limited drug choices. Should we continue to see these encouraging results in future studies and assuming that the safety of the drug is further realized in those studies, we believe that Proellex has the potential to become a major drug."
sorry about all the bold but this is kick ass news, and I think I just made a shit load of money on jan calls!!!!!
Thank you sputnick, for proving my point without a shadow of a doubt.
Not only have you not cleaned up your act, you just took it three steps lower.
There's a mental health facility pretty close by. You might want to look into patronizing it, rather soon.
cyo,
I'm sorry but this is just nonsense
it's not even worth continuing
percentages are not calculated in reverse, it's just not possible
sputnick,
who do you think you are? You have no idea of what I did or did not do WRT my investment in ITKG. You are acting like trailer trash, and I think you ought to be slightly more mature if you're older than 14. You're embarassing yourself, too. Somehow I think that's more of a lifestyle for you and not an isolated decision. Keep it up though, it seems to be defining you quite well.
well, my reply was to sputnock but at least you have enough sense to realize how you're acting plasipuk, --- you knew I was talking about you LOL
pretty much proves my point
grow up please you're embarassing yourself and your mother if she's got any sense
you two act like a bunch of 12 year old girls would
grow some class, please
flip:
no
RPRX
I believe that increased T, back to normal or low normal, will qualify as a clinical endpoint in and of itself.
I agree that there should be a HUGE run going on now, and all the cautious buying is a little frustrating to watch after this long waiting.....
also agree that if the fibroid data is even half as positive as the first two, $20 is not even close to overbought for what we have going on!
Let'er rip
A short has both the unlimited potential for a gain or loss.
CYO READ WHAT YOU WROTE
If you short a $100 stock, you get $100 in your account.
How in the world can you get an unlimited gain, from having a $100 transaction in your account?
You can't.
639hgr
Apologies I sometimes forget the level of sophistication on these pinky stock board.
Any textbook in finance will clearly explain that the maximum gain on any short position is 100%.
It's the gain compared to the original share price. Not the covering amount. The opposite side of the coin, if the stock takes off and you don't cover is shown in the first derivative of the yield curve for a short position, as delta N goes to infinty so do the losses....to infinity
CYO-
OK, so if you short XYZC at $100 and it does an Enron and goes to $0, there's no covering, right? your argument is that the return is what?
$100 gain over $0= what?
OT JBOG
'92 Finance
2nd Dev years 1&2, behind Hickey Tavern years, 3,4 and um 5!
RPRX- Good!
We'll know Friday won't we?
RPRX
1)290 M Worth of Androgel sales say yes it's worth it
2)increasing T is a clinical endpoint in and of itself, it's a hormone that helps regulate a LOT of physiological functions, not simply sex drive
RPRX NEWS
THE WOODLANDS, Texas, Dec 20, 2006 (BUSINESS WIRE) -- Repros Therapeutics Inc. (NasdaqGM:RPRX)(PCX:RPRX) announced interim results of a U.S. Phase 3 study of Androxal(TM), an oral drug that restores normal testicular function, for the treatment of testosterone deficiency in men with secondary hypogonadism. The Company has closed enrollment in the trial at 194 patients. These results suggest that, at this time in the study, treatment with Androxal results in a statistically significant increase in mean testosterone. Further, Androxal demonstrates non-inferiority in all parameters measured, in all the primary endpoints of the study, compared to Androgel(R), a commercially available testosterone replacement cream marketed for the treatment of low testosterone.
Study Details and Results
This double-blind study compares two doses of Androxal, 12.5 mg and 25 mg, to both placebo and open-label Androgel(R), which was dosed according to physician instructions (including use of higher doses where indicated). Testosterone levels as well as subjective measures of libido and distress were assessed in study participants. The study's primary endpoint is non-inferiority of Androxal in comparison to Androgel. To date, 112 patients have completed 12 weeks of treatment and have had analyses completed for their study parameters.
In this interim analysis, men treated with 12.5 mg of Androxal experienced an increase in mean testosterone of 210 ng/dl (p value less than 0.0001) over baseline; those treated with 25 mg of Androxal experienced an increase of 241 ng/dl (p value less than 0.0001) over baseline; and those treated with open-label Androgel, administered at any dose, experienced an increase of 167 ng/dl (p value = 0.0002) over baseline. As expected, men receiving placebo experienced no statistically significant change in mean testosterone.
Although neither men treated with Androxal nor those treated with Androgel reported a significant increase in libido as determined using the DISF-SRII scale at this interim analysis, both doses of Androxal performed comparably to Androgel. Likewise, although no statistically significant differences in distress, as measured by the MSDS scale, were recorded for men receiving Androxal or Androgel, both doses of Androxal performed in similar fashion to Androgel. Numerically, the 25 mg dose of Androxal produced the greatest reduction in distress followed by the 12.5 mg dose. However, as noted above the size of the data set at this time did not allow for a statistically significant difference compared to placebo. Both the DISF-SRII, a validated libido questionnaire and the Male Sexual Dysfunction Survey (MSDS), a questionnaire focusing on distress associated with low testosterone, have been developed by Dr. Leonard DeRogatis, Ph.D., Director of the Center for Sexual Medicine at Sheppard Pratt, a private non-profit provider of behavioral health services based in Maryland.
"We are very encouraged by these data," commented Joseph Podolski, President and CEO of Repros. "Androxal appears, at this interim analysis, to have met the study's primary endpoint, so we certainly look forward to concluding this trial and analyzing the full and complete data set. Moreover, we were impressed by the consistency with which Androxal produced increases in mean testosterone in men taking either dose. We anticipate completing this trial in the first half of 2007 and will provide our shareholders with an update on the final analysis when it is available." Mr. Podolski continued, "With these encouraging results in hand, we will seek to identify a licensing partner for Androxal in Europe."
Repros anticipates conducting at least two additional Phase 3 pivotal studies before submitting a New Drug Application to the U.S. Food and Drug Administration.
..................................................................
Now I sure do hope some of the big boys haven't been, ahem, putting downward pressure, on the stock in hopes of picking up shares on the cheap directly from the company because a partner in Europe might just fulfill ALL the needs of cash to see them through to completion of all 3 NDA's. Great news and expect to see a HUGE bump in the next 10 days, Especially if their fibroid news is out and is equally great this month.
Oh. My. God.
Is this the most biggest coincidence EVER?????
OK here's the site:
http://biketothebeach.ms150.org/btb/
Now, search down to the steering committee, look for "Gordon Dial".
D-I-A-L
Ok ready? Look two spaces above that, on the same committee!
Any names look familiar?
Is this a coincidence?
pretty big one, if so
cyo, I am not going to get into a long drawn out discussion about it, but rest assured that I know what I'm talking about.
In the example I cited the potential profit is only $100 per share on a $100 stock.
Your example makes the argument that the profit is limited only to the amount covered by, but if it's not covered, by your argument the profit is infinity. The potential losses in shorting are infiinty, therfore the potential profit are the inverse, 1, or 100%
Just like going long the potential gains are infinnity theortically, but the potential losses are only 100%. without margin of course.
Things are getting a little heated over there at the cesspool of filth and lies called raging bull. The longs are starting to lose their grip on the propaganda machine over there, too.
Nice to see truth justice and the American way take hold at yet another internet site, leaving the drippings of our selfish greedy society and its evil lying ways choking and sputtering in the lonely gutter.
Cyo,
Second, your assumption that shorts can't cover is ludicrous. GFCI is at an all time low. If the shorts sold their shares a month ago, they would have doubled their money.
Just FYI, the maximmu you can make with a short position is 100%.
Sell 100 shares of xxxx for $1 each, you get $100.
Stock goes to .001 you buy it back for 10 cents. Your profit was in effect 100% or double the money you needed to short it in the first place.
five and a half cents
congrats are in order stronguz
sputnick,
what a classy person you must be in real life
geeze
best2,
If you've been around a while you will remember when they announced the first record date. At that time I stated that it was a farce, because Jim Dial told me that there wouldn't be a ex-dividend date.
I told everyone again and again that there had to be a ex-div date and was met with guffaws, ridicule, and all out character attacks for my claim that it was impossible to NOT have an ex-dividend date.
Well, you read it here first. I mus apologize to all those I said was wrong about that. You all were right on target....there certainly never was any ex-dividend date!
Jim Dial keep playing the same tune, with a alightly different song title and one half key lower. This is called, announce a record date for the warrants, as opposed to the last time he played, announce a record date for the dividend shares....
this one won't happen either, imo
dialer keeps making excuses to do things that he claims is trapping naked shorty, yet strangely, they also allow for him to theoretically sell millions and millions of shares on the open market
The sad thing is, that if there really were a naked short position( there isn't of course, but we'll allow the longs favorite argument for a moment ) then somewhere there's a carte blanche toggle switch allowing more and more and more and more shares to be printed, which if you allow the law of supply and demand to take precedence, unlimited supply always leads to a price of you guessed it, $0
IOW, for their sake they had better hope that there's NOT a naked short position, because there's not going to be anything anyone can do to right the ship, if so.....
fair? no way, but that's why you NEVER buy and hold pinks
BBB you just don't get it, do you?
A PR about tranches, and gas leases
what about the venezuelan order, the al haig show, the jet motor. What about the buyout offer for $1.25 per share? Actually 3 of them! What about the $2.25 buyout offer? What about the Coil Tubing spinout and dividend? What about what about what about. 2 Million per month per each 50 jet motors.
Whether it be incompetence huscksterism or just plain adult onset attention defecit disorder or a drinking problem, Jim Dial has not gotten one single thing done that he's PR'd.
Just like he won't complete a merger with moose drool inc, what's their name, tree toppers????
Just like there's not going to be any gas wells dropped in the next 30 days
Just like there's no warrants
Just like there'a no Jet Motor increasing each well by 25%
just like there will NEVER be a dividend
Just like there will NEVER be audited financials or any published share counts
You invest in coca-cola for the long term, GE, Tootsie Roll, you don't invest in a non reporting pinkie for the long run and you certainly don't invest enough to be hiring PI's and attorneys to verify your suspicions of the company....
this is getting sad................it used to be amusing to see you be so wrong especially after the grief you and your cronies gave me, but this is really no even interesting except from a trainwreck perspective
10Bag
don't bother to ask any questions
there is no longer any honor, or integrity, or even any ethics, among the people who are long and making excuses for grift-co
hoping to recoup some of their 70% to 95 % lossses...
dont' bother asking BB questions
he won't answer
asked him a question to confimr a statement he made, actually several, and he was again strangely silent...
POST 8166 remains unanswered and until then it's just as if jim dial was speaking through a ihub source...just jam the guesses together and don't clarify anything.
Don't worry he writes pretty though,
strongus you're strangely silent these days
I am without substance strongus?
I am positive I am better at trading than you are